利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

984 条记录 (耗时 0.043 秒)

    COMPOSITIONS AND METHODS FOR INHIBITING CBP80 BINDING TO PGCI FAMILY OF CO-ACTIVATORS
    3.
    发明申请
    COMPOSITIONS AND METHODS FOR INHIBITING CBP80 BINDING TO PGCI FAMILY OF CO-ACTIVATORS 审中-公开
    抑制CBP80结合PGCI家族共激活因子的组合物和方法

    公开(公告)号：WO2017099821A1

    公开(公告)日：2017-06-15

    申请号：PCT/US2016/000126

    申请日：2016-12-08

    申请人： UNIVERSITY OF ROCHESTER

    发明人： GLEGHORN, Michael ,  MAQUAT, Lynne ,  FASAN, Rudi

    IPC分类号： C07K7/08 ,  C07K14/47 ,  A61K38/04

    CPC分类号： C07K14/4747 ,  A61K38/00 ,  C07K7/08

    摘要： The invention provides compositions and methods for inhibiting protein- protein interactions with cap-binding protein 80 (CBP80). In one embodiment, the invention provides compositions comprising linear and macrocylic peptides. In one embodiment, the invention provides methods for treating cancer, heart disease, autoimmune disorders, obesity, diabetes, or chronic inflammation disorders associated with the PGC1 family of co-activators.

    摘要翻译： 本发明提供了抑制蛋白质 - 蛋白质与帽结合蛋白80（CBP80）相互作用的组合物和方法。 在一个实施方案中，本发明提供了包含线性和大环肽的组合物。 在一个实施方案中，本发明提供了治疗癌症，心脏病，自身免疫性病症，肥胖症，糖尿病或与共同激活剂PGC1家族有关的慢性炎症疾病的方法。

    METHODS AND COMPOSITIONS FOR SELECTIVELY ELIMINATING CELLS OF INTEREST
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR SELECTIVELY ELIMINATING CELLS OF INTEREST 审中-公开
    选择性消除感兴趣细胞的方法和组合物

    公开(公告)号：WO2016094888A1

    公开(公告)日：2016-06-16

    申请号：PCT/US2015/065421

    申请日：2015-12-14

    申请人： ZHU, James

    发明人： ZHU, James ,  ZHANG, Yi

    IPC分类号： C12N15/85 ,  C12N9/22 ,  C12N15/113 ,  C12N15/52 ,  A61K48/00 ,  C12Q1/68

    CPC分类号： C12N9/22 ,  A61K48/005 ,  C07K14/4747 ,  C12N9/6472 ,  C12N9/78 ,  C12N15/102 ,  C12N15/111 ,  C12N15/113 ,  C12N15/52 ,  C12N15/63 ,  C12N15/907 ,  C12N2310/20 ,  C12N2320/30 ,  C12N2750/14143

    摘要： The present disclosure provides novel compositions and methods suitable for specifically eliminating target cells (e.g., cancer cells) without affecting non-target cells (e.g., non-cancer cells). For example, CRISPR system and the compositions of the present disclosure can be employed to specifically introduce a suicidal gene into a cancer cell in the loci of a cancer-specific target sequence, which as a result of chromosomal re-arrangement or translocation in a cancer cell presents a cancer specific sequence for a guide RNA and CAS to be recognized and such sequence is absent in a non-cancer cell. Consequently, the specific introduction of the composition(s) to cancer-specific site(s) and integration of suicide gene in the target genome, which is inapplicable to normal cells for lack of the site(s), leads to selective elimination of cancer cells but not non-cancer cells, and therefore render novel therapeutic methods and compositions for cancer treatment.

    摘要翻译： 本公开提供适用于特异性地消除靶细胞（例如癌细胞）而不影响非靶细胞（例如非癌细胞）的新型组合物和方法。 例如，CRISPR系统和本公开的组合物可用于特异性地将癌基因特异性引入癌症特异性靶序列的基因座中的癌细胞中，其作为癌症中染色体重排或易位的结果 细胞呈现用于指导RNA和CAS的癌症特异性序列以被识别，并且在非癌细胞中不存在该序列。 因此，组合物特异性地引入癌基因特异性位点并将靶向基因组中的自杀基因整合到由于缺少位点而不适用于正常细胞，导致癌症的选择性消除 细胞，但不是非癌细胞，因此提供用于癌症治疗的新型治疗方法和组合物。

    ENGINEERED HIGH-AFFINITY HUMAN T CELL RECEPTORS
    8.
    发明申请
    ENGINEERED HIGH-AFFINITY HUMAN T CELL RECEPTORS 审中-公开
    工程高度人类细胞受体

    公开(公告)号：WO2015077607A1

    公开(公告)日：2015-05-28

    申请号：PCT/US2014/066892

    申请日：2014-11-21

    申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

    发明人： SMITH, Sheena N. ,  HARRIS, Daniel T. ,  KRANZ, David M.

    IPC分类号： C07K14/725 ,  A61K38/17 ,  A61P35/00

    CPC分类号： C07K14/7051 ,  A61K38/00 ,  C07K14/4747 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92

    摘要： T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.

    摘要翻译： 提供了对存活素抗原具有较高亲和力的T细胞受体（TCR）。 通过以单链形式产生TCR的突变文库，随后选择提高酵母表面的稳定性和亲和力（即定向进化），来设计高亲和性TCR。 在实施方案中，工程化TCR可以以可溶形式用于体内靶向递送，或者作为在过继性T细胞设置中导入T细胞的基因。

    SHORT PEPTIDES DERIVED FROM VDAC1, COMPOSITIONS AND METHODS OF USE THEREOF
    9.
    发明申请
    SHORT PEPTIDES DERIVED FROM VDAC1, COMPOSITIONS AND METHODS OF USE THEREOF 审中-公开
    从VDAC1衍生的短肽，组合物及其使用方法

    公开(公告)号：WO2015011711A1

    公开(公告)日：2015-01-29

    申请号：PCT/IL2014/050675

    申请日：2014-07-24

    申请人： THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.

    发明人： SHOSHAN-BARMATZ, Varda

    IPC分类号： C07K7/00 ,  C07K14/705 ,  C07K19/00 ,  A61K38/04 ,  A61P35/00

    CPC分类号： C07K14/4747 ,  A61K38/00 ,  A61K47/645 ,  C07K14/43581 ,  C07K2319/00

    摘要： The present invention relates to short peptides based on the amino acids sequence of the N-terminal domain of the human mitochondrial protein voltage-dependent anion channel 1 (VDAC) and to peptide conjugates further comprising a cell permeability enhancing moiety. The peptides, peptide conjugates and pharmaceutical composition comprising same are useful for treating diseases characterized by cell hyperproliferation or resistance to cell death, particularly cancer.

    摘要翻译： 本发明涉及基于人线粒体蛋白电压依赖性阴离子通道1（VDAC）的N-末端结构域的氨基酸序列的短肽和进一步包含细胞渗透性增强部分的肽缀合物。 肽，肽缀合物和包含其的药物组合物可用于治疗特征在于细胞过度增殖或抗细胞死亡特别是癌症的疾病。